KRRO
Korro Bio, Inc.
There isn't enough reported data to score KRRO yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
KRRO Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Weak | |
| Unavailable |
KRRO's profitability and cash flow are currently weak. There isn't enough data to rate its revenue and balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
KRRO PE Valuation
KRRO has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
KRRO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| -- | |
| Limited | |
| Low |
Analysts expect KRRO's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
KRRO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$9.07 | +$0.32 |
| Q2 2026 | -$10.01 | -$0.28 |
| Q1 2026 | -$11.68 | -$2.26 |
| Q4 2025 | -$12.48 | -$3.11 |
| Q3 2025 | -$9.39 | +$49.67 |
| Q2 2025 | -$9.73 | +$62.57 |
| Q1 2025 | -$9.42 | +$75.23 |
| Q4 2024 | -$9.37 | +$100.17 |
KRRO is still losing money, but far less than before: $9.07 per share over the past year, against $131.50 at its worst in mid-2022.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over KRRO on earnings quality, reporting a profit while its opponent remains loss making.
KRRO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2021 | $9.4M | +10% |
| Q1 2021 | $4.7M | -36% |
| Q4 2020 | $10M | +111% |
KRRO's revenue has slid since its 2020 peak: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | -3901% | N/A |
| Q3 2025 | -1765% | N/A |
| Q2 2025 | -1863% | N/A |
| Q1 2025 | -981% | N/A |
| Q2 2021 | -186% | -113 points |
| Q1 2021 | -434% | -356 points |
| Q4 2020 | -103% | +35 points |
| Q3 2020 | -48% | N/A |
KRRO's operating margin was −3901% last quarter, down 3715 points from the same quarter a year ago, near the bottom of its range since 2019.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over KRRO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
KRRO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$13M | +$4.4M |
| Q2 2026 | -$17M | +$2.3M |
| Q1 2026 | -$16.1M | +$8.5M |
| Q4 2025 | -$17.8M | -$8.8M |
| Q3 2025 | -$17.4M | +$3.6M |
| Q2 2025 | -$19.4M | +$1.2M |
| Q1 2025 | -$24.6M | +$2.9M |
| Q4 2024 | -$8.9M | +$38.7M |
KRRO has burned cash in almost every quarter: −$64M over the past year, against −$70M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over KRRO on cash generation, producing positive trailing cash flow while its opponent burns cash.
KRRO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.4% | +249K shares |
| 1 year | +90% | +8.5M shares |
| 3 years | +2399% | +17.2M shares |
| 5 years | +2519% | +17.2M shares |
| Available history | +2794% | +17.2M shares |
KRRO has 18M diluted shares, up 90% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over KRRO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
KRRO Net Leverage
KRRO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
KRRO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 55.3 | Neutral |
| Stochastic | 75.0 | Neutral |
KRRO's weekly RSI is 55 (neutral) and its Stochastic is 75 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
KRRO PE vs Healthcare Sector
KRRO has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
KRRO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $11.7 | 23% above |
| 20 week MA | $12.2 | 17% above |
| 50 week MA | $11.6 | 23% above |
| 100 week MA | $18.0 | 20% below |
| 200 week MA | $32.3 | 56% below |
KRRO has bounced recently, but its long-term trend is still down: it's above its 8-, 20- and 50-week averages, but 56% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over KRRO on trend strength, trading above more of its moving averages.
KRRO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $917.0 | $1,686.0 | +84% |
| 2021 | $1,686.0 | $272.0 | -84% |
| 2022 | $272.0 | $129.5 | -52% |
| 2023 | $129.5 | $47.9 | -63% |
| 2024 | $47.9 | $40.0 | -17% |
| 2025 | $40.0 | $8.12 | -80% |
| 2026 YTD | $8.12 | $14.3 | +76% |
KRRO has the edge over LLY on returns for 2026, with the stronger performance.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.